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Introduction: Mesenchymal stem cells (MSCs) have the ability to proliferate in vivo with a large variety of differentiation
potentials and therefore are widely used as an ideal material for cell therapy. MSCs derived from pig and human
sources are similar in many aspects, such as cell immunophenotype and functional characteristics. However, differences
in proteomics and the molecular mechanisms of cell functions between porcine bone marrow MSCs (BM-MSCs) and
umbilical cord MSCs (UC-MSCs) are largely unknown. To the best of our knowledge, MSCs collected from different
tissue have specific phenotype and differentiation ability in response to microenvironment, known as a niche.
Methods: Porcine BM-MSCs and UC-MSCs were evaluated with flow cytometric and adipogenic and osteogenic
differentiation analyses. We used isobaric tagging for relative and absolute quantitation (iTRAQ), combined with
liquid chromatography-tandem mass spectrometry, to identify differentially expressed proteins (DEPs) between
these two types of MSCs. Kyoto Encyclopedia of Genes and Genomes pathway and phenotype analyses were
used to understand the links between cell migration ability and DEPs.
Results: Two separate iTRAQ experiments were conducted, identifying 95 DEPs (95% confidence interval). Five of
these proteins were verified by Western blotting. These 95 DEPs were classified in terms of biological regulation,
metabolic process, developmental process, immune system process, reproduction, death, growth, signaling,
localization, response to stimulus, biological adhesion, and cellular component organization. Our study is the first
to show results indicating that porcine BM-MSCs have a higher migration capability than UC-MSCs. Finally, one of
the DEPs, Vimentin, was verified to have a positive role in MSC migration.
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Conclusions: These results represent the first attempt to use proteomics specifically targeted to porcine MSCs of
different tissues. The identified components should help reveal a variety of tissue-specific functions in tissue-derived
MSC populations and could serve as important tools for the regeneration of particular tissues in future stem cell-based
tissue engineering studies using animal models.Introduction
Mesenchymal stem cells (MSCs), which are a type of
adult stem cell developed from the mesoderm, can be
isolated from the brain, liver, lung, kidney, fat, bone mar-
row, peripheral blood, umbilical cord blood, umbilical
cord, placenta, amniotic fluid, and other tissues [1].
MSCs possess the potential for self-renewal and pluripo-
tency and play an important role in tissue repair and re-
generation [2]. When cultured in vitro, MSCs exhibit
strong proliferation and can be induced to differentiate
into bone, cartilage, adipogenic, and myogenic tissue;
therefore, MSCs are widely used for bone and muscle re-
pair in pre-clinical evaluation and clinical studies [1]. In
addition, extensive clinical studies on MSC-based ther-
apies have been conducted on many human diseases, in-
cluding chronic graft-versus-host disease, systemic lupus
erythematosus, cirrhosis, diabetes, acute kidney injury,
and a variety of neurodegenerative diseases [1]. Bone
marrow MSCs (BM-MSCs) are an important source of
the adult stem cells widely used in basic and clinical re-
search [3]. However, these cells are limited by the incon-
venience of sample collection and by a reduced
proliferation and differentiation capacity, coupled with
effects of the donor’s age [2]. Therefore, searching for
the detailed mechanism underlying these phenotypes
and eliminating these limitations are important. In con-
trast, some studies have shown that umbilical cord
MSCs (UC-MSCs) are similar to BM-MSCs regarding
cell surface markers, physiological characteristics, prolif-
eration and differentiation characteristics, and protein
expression spectra; therefore, similar to BM-MSCs, UC-
MSCs may be used for allogeneic stem cell transplant-
ation in cell regeneration therapy [4]. MSCs that reside
in different microenvironments have many similarities;
however, a detailed comparison between BM-MSCs and
UC-MSCs is required to verify their potential for use in
clinical therapy.
In recent years, miniature pigs have been widely used
as an animal model in stem cell biology, which is im-
portant for the treatment of human diseases and for
xenotransplantation. Because the organ size, physio-
logical level, genetic characteristics, and other aspects
of the pig model are similar to those of humans, the
findings on porcine stem cells may provide a theoretical
basis and practical guidance for clinical applications in
human diseases [5]. Therefore, it may be possible touse pig-derived stem cells as an alternative resource to
treat human diseases. However, some researchers have
shown that different sources of MSCs exhibited differ-
ences in gene expression patterns under specific culture
conditions [3,6]. In addition, these cells could produce
specific organizational structures depending on their
growth environment and on their response to different
ectopic microenvironments, thereby differentiating into
different cell types [7]. Therefore, it is important to
understand the molecular basis of these features and
signaling mechanisms of MSCs for the clinical applica-
tion of cell therapy. Analyzing gene expression levels
and taking advantage of chip or sequencing technology
would help us to understand the molecular mechanism
of cellular functions; however, transcript level informa-
tion may not completely overlap with protein levels [8].
Therefore, proteomic research would aid in under-
standing the molecular mechanism of MSC differenti-
ation [6]. Compared with transcriptome data, proteome
analysis could be used to study many aspects of the
proteome, including protein expression levels, protein
stability, subcellular localization, post-translational
modifications, and protein interactions [8]. However,
there are some limitations to proteomic approaches
based on two-dimensional electrophoresis and mass
spectrometry (MS) techniques. For example, detecting
hydrophobic proteins and phosphorylated proteins is
difficult [9]. These limitations have driven the develop-
ment of new technologies for protein identification and
quantitation. iTRAQ (isobaric tagging for relative and
absolute quantitation) is a gel-free technique used in
quantitative proteomic analysis that can identify low-
abundance proteins [9]. This type of proteomic analysis
may help researchers to understand the proteomic dif-
ferences of diverse sources of MSCs.
A proteomic analysis of MSCs was first reported in
2001 [6]. Since then, MS-based proteomic technology
has increasingly become an effective tool for detecting
differentially expressed proteins (DEPs) of MSCs derived
from various sources or in the state of in vitro differenti-
ation [10]. Researchers have used proteomic technology
to identify DEPs of human MSCs in the process of
osteogenic differentiation [11]. In another study, rabbit
BM-MSCs were induced by 5-azacytidine (5-aza) to dif-
ferentiate into myocardial cells, and the resulting prote-
omic changes were analyzed [12]. Welsh et al. identified
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genic differentiation of MSCs [13]. However, MSCs de-
rived from various sources exhibit differences in their
protein expression profiles [6]. A proteomic comparison
between BM-MSCs and UC-MSCs has already been re-
ported for humans but not for large animals, such as
pigs. Neng Seng et al. conducted a comparative analysis
of the proteome of BM-MSCs in different generations
isolated from Chinese miniature pigs only [14], and their
research did not include a comparison of MSCs derived
from different tissues. In the study of human MSCs,
Guo Li et al. compared the proteome of BM-MSCs and
UC-MSCs and then studied different proteins associated
with cell migration [2]. Given the limitation in collecting
human specimens, their experiment used a two-to-two
design, and the two-dimensional electrophoresis-based
MS and tandem MS (MS/MS) analysis detected only six
DEPs between these two types of MSCs. Therefore, it is
important to use an animal model, such as the pigs de-
scribed above, and sensitive proteomic detection to un-
cover the differences between MSCs. In this study, we
compared the DEPs from match-paired BM-MSC and
UC-MSC samples, which were collected from the same
piglets and cultured under identical conditions, and
found 95 DEPs involved in different aspects of cell biol-
ogy, especially cell motility. Additionally, iTRAQ quanti-
tative proteomic techniques were used to clarify DEPs
between BM-MSCs and UC-MSCs obtained from
Wuzhishan mini-pigs. Accuracy of the results was
assessed by Western blot. The results from these ex-
periments indicate that the protein expression profiles
of these two types of MSCs such as Vimentin,
LGALS3, and TMSB4X are largely distinguishable in
terms of cell motility.
Methods
Animals
The Animal Care Committee of the Chinese Academy of
Agricultural Sciences approved all animal procedures. The
newborn pigs were purchased from the National Germ-
plasm Resources Center of Laboratory Miniature Pig.
Isolation and culture of porcine mesenchymal stem cells
The MSCs were isolated from porcine umbilical cord
(UC-MSCs) and bone marrow (BM-MSCs) as described
previously. Briefly, the umbilical cords were collected
when the piglets were born, and intact femurs were har-
vested from the same four Wuzhishan inbred pigs
(WZSP) (Institute of Animal Sciences, Chinese Academy
of Agricultural Sciences, Beijing, China) by sterile ope-
ration at 42 days after birth. The umbilical cord tissue was
diced into 2- to 3-mm3 pieces, and the MSCs were sepa-
rated by using a substrate-attached explant method. The
bone marrow stem cells were extracted and centrifuged at200 g for 5 minutes. The isolated MSCs were cultured in
Dulbecco’s modified Eagle’s medium/F12 (DMEM/F12)
(12500; Gibco, part of Life Technologies, Carlsbad, CA,
USA) medium with 20% (vol/vol) fetal bovine serum
(10099; Gibco), 50 units/mL penicillin G, and 50 μg/mL
streptomycin and incubated at 37°C under 5% (vol/vol)
CO2 in 100% humidified air. The media were changed
every other day. The MSCs were harvested by digestion
with 0.05% (wt/vol) trypsin-EDTA (25300054; Gibco)
when the rate of cell fusion reached 80%. Cells were
replanted in 100-mm dishes at a density of 1 × 104/cm2.
The evaluation of mesenchymal stem cells by flow
cytometric analysis
The cultured MSCs were digested with 0.05% (wt/vol)
trypsin-EDTA (Gibco), followed by washing with cold
autoMACS Rinsing Solution (2°C to 8°C; Miltenyi
Biotec, Bergisch Gladbach, Germany) three times. The
pellets were resuspended in 1% (wt/vol) bovine serum
albumin (Sigma-Aldrich, St. Louis, MO, USA) for 30 mi-
nutes at 4°C to block non-specific binding. Then, the
UC-MSCs were incubated with rat anti-mouse CD31-
APC (PECAM-1) (Miltenyi Biotec), mouse anti-human
CD34-PE (Miltenyi Biotec), mouse anti-human CD45-PE
(Miltenyi Biotec), or mouse anti-human CD90-FITC
(Thy-1) (Abcam, Cambridge, MA, USA) monoclonal
antibodies at 4°C for 30 minutes, respectively. The BM-
MSCs were incubated with mouse anti-human CD29-
FITC (Miltenyi Biotec), mouse anti-human CD34-PE
(Miltenyi Biotec), rat anti-mouse CD44-FITC (Miltenyi
Biotec), mouse anti-human CD45-PE (Miltenyi Biotec),
or mouse anti-human CD90-FITC (Thy-1) (Abcam)
monoclonal antibodies at 4°C for 30 minutes, respect-
ively. The flow cytometric acquisition and data analysis
were performed by using a BD FACSCalibur flow cyt-
ometer and Cell Quest software (BD Biosciences, San
Jose, CA, USA). As a negative control, cells were incu-
bated only with the corresponding isotype antibody, in-
cluding rat IgG2a-APC (used for CD31; Miltenyi Biotec),
mouse IgG2a-PE (used for CD34 and CD45; Miltenyi
Biotec), rat IgG2b-FITC (used for CD44; Miltenyi Bio-
tec), and mouse IgG1-FITC (used for CD29 and CD90;
Miltenyi Biotec). These specimens could be placed in 4%
paraformaldehyde for short-term preservation. Three in-
dependent flow cytometric experiments were performed.
Adipogenic and osteogenic differentiation of
mesenchymal stem cells
To evaluate MSC abilities, adipogenic and osteogenic
differentiation assays were performed on isolated cells.
Osteogenesis differentiation medium (Gibco) or adipo-
genesis differentiation medium (Gibco) was added into a
culture when the fusion rate reached approximately 80%.
The cells were cultured at 37°C in 5% (vol/vol) CO2 in
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3 days, and the cells were cultured for 2 to 3 weeks be-
fore collection. Then, Alizarin Red S staining was used
to analyze osteogenic lineages, whereas Oil Red O was
used to analyze lipid droplets. Adipogenic and osteo-
genic differentiation assays were conducted three times
for all four donor cells.Trypsin digestion and iTRAQ labeling
All the reagents and buffers required for iTRAQ labeling
and cleaning were purchased from Applied Biosystems
(Foster City, CA, USA). The iTRAQ labeling assay was
conducted in accordance with the instructions of the
manufacturer. Briefly, after digestion in culture flasks,
total MSCs were collected and washed with cold
phosphate-buffered saline (PBS) three times (2°C to 8°C).
Cell pellets were directly used for extracting proteins or
frozen in −80°C. The protein extraction process was car-
ried out on ice in cold lysis buffer containing complete
protease inhibitor cocktail (Roche, Basel, Switzerland).
Proteins were stored in −80°C. Repeated freeze-thaw cy-
cles were avoided. The proteins were dissolved in 8 M
urea supplemented with 10 mM DTT, pH 8.5 (Amesco,
St. Louis, MO, USA), and protein concentrations were de-
termined by using the Bradford assay. Proteins were dis-
solved, denatured, alkylated, and digested with trypsin
(Sigma-Aldrich; 1:20, wt/wt, 37°C for 18 hours). To label
peptides with the iTRAQ reagent, 1 unit of label (defined
as the amount of reagent required to label 100 μg of pro-
tein) was thawed and reconstituted in 70 μL of ethanol.
The digestion reactions from UC-MSCs and from BM-
MSCs were separately labeled with the 114 and 117
iTRAQ reagents, respectively. To identify more proteins,
a strong cation exchange column (Applied Biosystems)
was used to separate the mixed peptides. The elution
buffers used were elution buffer A, containing 5 mM
K2HPO4 in 20% (vol/vol) acetonitrile at pH 3.0, and elu-
tion buffer B, containing 5 mM K2HPO4 in 20% (vol/vol)
acetonitrile and 350 mM KCl at pH 3.0. The labeled pep-
tides were reconstituted in phase A and injected at a flow
rate of 0.7 mL/minute into a high-resolution strong cation
exchange (SCX) column (4.6 × 250 mm 5 μm; Thermo
BioBasic, USA). After loading, the SCX column and C 18
precolumn were flushed with a three-step gradient sodium
chloride solution (0, 50, and 100 mM) for 66 minutes.
Then, the elution of the cation exchange groups was
performed with an Agilent 1100 series high-performance
liquid chromatography (HPLC) system, which was
equipped with an autosampler, a 2/6 valve, and diode array
detector (220 nm) (Agilent, Waldbronn, Germany), and
35 fractions were collected. Before liquid chromatog-
raphy-MS/MS (LC-MS/MS), each fraction was desalted
by using an SP-10 precolumn.Analysis by triple quadrupole time-of-flight tandem mass
spectrometer
The eluted fractions were delivered into a nano reversed
phase column (5-μm Hypersil C18 column, 75 μm×
150 mm; Thermo Fisher Scientific, Waltham, MA, USA)
mounted in a Prominence Nano HPLC system (Shimadzu,
Nakagyo-ku, Kyoto, Japan) and were eluted with an aceto-
nitrile gradient from 5% to 40% containing 0.1% formic
acid for 75 minutes at 400 nL per minute. The eluates were
directly entered into a triple quadrupole time-of-flight
(TOF) 5600 System (AB Sciex, Concord, ON, Canada),
which was fitted with a Nanospray III source (AB
Sciex) and with a pulled quartz tip as the emitter (New
Objectives, Woburn, MA, USA), in positive ion mode and
in a data-dependent manner, with full MS scan from 350
to 1,800 m/z.
The data were acquired by using an ion spray voltage
of 2.5 kV, a curtain gas of 30 pounds per square inch
(PSI), a nebulizer gas of 6 PSI, and an interface heater
temperature of 150°C. The MS was operated with a re-
solving power of 30,000 full width at half maximum
(FWHM) for TOF-MS scans. For information-dependent
acquisition, survey scans were acquired in 250 millisec-
onds, and as many as 20 product ion scans were collected
when exceeding a threshold of 125 counts per second,
with a +2 to +5 charge state. A rolling collision energy set-
ting was applied to all precursor ions for collision-induced
dissociation. Dynamic exclusion was set at half the peak
width (approximately 8 seconds), and then the precursor
was refreshed off the exclusion list.
Database searching and protein quantitation
In this study, we used ProteinPilot software 4.0 (AB
Sciex, Foster City, CA, USA), including the Paragon™
and Pro Group™ algorithms, to interpret raw data files
produced by MS. The parameters for searching were as
follows: iTRAQ four-plex peptide labeled, trypsin diges-
tion with only 1 maximum missed cleavage, carbamido-
methylation for cysteine residues, variable oxidation for
methionine, quadrupole TOF electrospray ionization,
and identification, focusing on biological modifications.
The tolerances were specified as ± 0.05 Da for peptides
and ± 0.05 Da for MS/MS fragments. The National Cen-
ter for Biotechnology Information and Swiss-Prot pro-
tein databases were chosen for searching, and the false
discovery rate was controlled at 1% by using the inte-
grated tools in ProteinPilot software. For protein assem-
bling, the Pro Group algorithm was used to find the
smallest number of proteins that could explain all the
fragmentation spectral evidence.
Protein quantification was also performed by using
ProteinPilot software, which automatically calculated the
relative abundance of iTRAQ-labeled peptides and their
corresponding proteins. Corrections were made for the
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provided by the manufacturer. For other similar errors
in analyses, iTRAQ ratios were normalized by autobias,
which used all data to calculate the bias correction
factor.
Gene Ontology annotation and enrichment analysis
DEPs were annotated by using the Sus scrofa Gene
Ontology (GO) annotations database (updated on Jan. 2,
2014). The GO enrichment analysis was based on GO
databases and was conducted by using tools displayed
on the GO website. All the databases and tools were
downloaded or linked from the website [15].
KEGG pathway analysis
Pathway analyses of DEPs were based on the Kyoto
Encyclopedia of Genes and Genomes (KEGG). The
KEGG application programming interface and related
databases were used to study the protein pathways. All
of the resources were acquired from the website [16].
Western blotting
The cells were washed with ice-cold PBS and lysed in
mammalian protein extraction reagent (Thermo Scien-
tific, Waltham, MA, USA) containing a protease inhibi-
tor mixture (Roche Applied Science, Indianapolis, IN,
USA). Cell lysates were centrifuged at 12,000 g for 10 mi-
nutes at 4°C, and the supernatant was collected. The
protein concentrations were measured by using the
Bradford protein assay with a Bicinchoninic Acid Protein
Assay Kit (Thermo Scientific). In total, 20 μg of total
protein was separated by 12% (wt/vol) SDS-PAGE and
transferred onto a polyvinylidene fluoride (PVDF) mem-
brane (Millipore, Billerica, MA, USA). Then, the mem-
brane was blocked with 2% (wt/vol) bovine serum
albumin (BSA) (Sigma-Aldrich) for 1 hour. Next, the
previously indicated primary antibodies were used to
probe the membrane overnight at 4°C. After extensive
washing with Tris-buffered saline with Tween 20 (TBS-T),
the membrane was incubated with secondary antibodies
for 1 hour at room temperature. Bands were visualized by
using SuperSignal West Pico Chemiluminescent Substrate
(Pierce, part of Life Technologies) and recorded on x-ray
films (Fuji Medical, Tokyo, Japan). Finally, the visualized
bands were quantified by using Quantity One software on
a GS-800 densitometer (Bio-Rad Laboratories, Hercules,
CA, USA). The antibodies used were as follows: CNN1/
calponin rabbit anti-human monoclonal (EP798Y) anti-
body (LifeSpan Biosciences, Inc., Seattle, WA, USA),
Vimentin (D21H3) XP rabbit anti-human mAb (Cell Sig-
naling Technology, Danvers, MA, USA), CTSB/cathepsin
B rabbit anti-human polyclonal antibody (LifeSpan Biosci-
ences, Inc.), TAGLN/SM22 rabbit anti-human polyclonal
(C-terminus) antibody (LifeSpan Biosciences, Inc.),galectin-3/LGALS3 rabbit anti-human polyclonal antibody
(Cell Signaling Technology), rabbit anti-mouse Akt poly-
clonal antibody (Cell Signaling Technology), Phospho-Akt
(Ser473) (D9E) rabbit anti-human monoclonal antibody
(Cell Signaling Technology), p44/42 MAPK (Erk1/2)
(137 F5) rabbit anti-rat monoclonal antibody (Cell Sig-
naling Technology), Phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204) (D13.14.4E) rabbit anti-human mono-
clonal antibody (Cell Signaling Technology), and
β-actin (13E5) rabbit anti-human monoclonal antibody
(Cell Signaling Technology).
RNA extraction and quantitative real-time polymerase
chain reaction
Total RNA was extracted by using a MicroElute Total
RNA Kit (Omega Bio-Tek, Norcross, GA, USA). The
comparative delta-delta threshold cycle (Ct) method
was adopted to analyze gene products by using the
SYBR Select Master Mix (Applied Biosystems) in a
7500 Real-Time Polymerase Chain Reaction System
(Applied Biosystems). Glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) was used as an internal control
gene to calculate the relative gene expression. The ex-
periment was repeated three times, and the results were
expressed as the mean ± standard deviation. The primer
sequences are reported in Additional file 1: Table S3.
Short interfering RNA transfection
Stealth short interfering RNA (siRNA) (Invitrogen, part
of Life Technologies) against vimentin was transfected
into the BM-MSCs. Non-targeting siRNA was used as a
control. The experiment was conducted in accordance
with the protocol of the manufacturer (Invitrogen).
Briefly, the cells were harvested and subcultured in
antibiotic-free medium for 12 hours. Then, the cells
were transfected when the rate of cell fusion reached
50%. The siRNAs were incubated with Lipofectamine
2000 (Invitrogen) for approximately 20 to 30 minutes
and diluted with Opi-MEM medium (Gibco). The trans-
fection mixture was gently added to the culture medium.
Six hours later, the culture medium was replaced with
fresh medium.
Lentivirus-mediated overexpression in cell culture
UC-MSCs were plated in 60-mm dishes at a density of
5 × 105 cells per dish. After 24 hours of cultivation, the
cells were infected with a sham control lentivirus or
lentivirus encoding porcine vimentin (LV5-NC or LV5-
vimentin, respectively; GenePharma, Shanghai, China) at
a multiplicity of infection of 100 in DMEM-F12 contain-
ing 10% fetal bovine serum (FBS). Twelve hours later,
these cells were processed for Western blotting and mi-
gration analysis.
Figure 1 (See legend on next page.)
Huang et al. Stem Cell Research & Therapy  (2015) 6:77 Page 6 of 18
(See figure on previous page.)
Figure 1 Mesenchymal stem cells were spindle-like and expressed certain protein markers on the cell surface. (A) Cell shape and growth states were
similar between bone marrow mesenchymal stem cells (BM-MSCs) and umbilical cord mesenchymal stem cells (UC-MSCs) in vitro. (B) As shown in the
overlay histograms, five cell surface markers of BM-MSCs were verified: CD29 (FITC, green), CD44 (FITC, green), and CD90 (FITC, green), which were
positive, and CD34 (PE, orange) and CD45 (PE, orange), which were negative. (C) Four cell surface markers of UC-MSCs were verified: CD90 (FITC,
green), which was positive, and CD31 (APC, red), CD34 (PE, orange), and CD45 (PE, orange), which were negative. FITC, fluorescein isothiocyanate;
PE, phycoerythrin.
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assay and by a transwell migration assay
MSC migration was assessed by using a scratch assay
and a transwell migration assay. The detailed process
was as follows: Cells were cultured in 60-mm dishes to
confluence and incubated with 10 μg/mL mitomycin-C
for 2 hours. The growth-arrested cells were transferred
into 24-well plates at a density of 8 × 104 per well. Six
hours later, ‘scratches’ were made along the bottom of
the dish by using a 200-μL pipette tip. Then, the cells
were cultured for another 48 hours. During incubation,
dishes were placed under a phase-contrast microscope
to acquire images at selected time points (6, 12, 24, 36,
and 48 hours).
The cells were placed in the upper chamber of the
transwell assembly (6.5-mm diameter inserts, 8.0-μm
pore size; Corning Costar, Corning, NY, USA) with
100 μL of FBS-free medium at a density of 5 × 104 or
2 × 105 cells/mL in 200 μL, and 800 μL of medium con-
taining 10% FBS as a source of chemoattractants filled
the lower compartments. Cell number in the upper
chamber of the transwell was not a coincidence among
the three series of migration assays. For example, the cell
number was 4 × 104 per well in the migration assay of
wild-type BM-MSCs and UC-MSCs or Vimentin-
overexpressed BM-MSCs, respectively. However, in the
migration assay of Vimentin-knocked-down UC-MSCs,
the cell number was only 1 × 104. After incubation at 37°C
for 12 hours, the membrane was stained with Hoechst
33342 (Beyotime Institute of Biotechnology, Haimen,
China), and the number of migrating cells was deter-
mined by counting 10 random fields per well under a
fluorescence microscope at 40× magnification. Experi-
ments were performed in sets of three for each group.
Results
Isolation, culture, and cell marker detection of porcine
mesenchymal stem cells
The cell type and growth state of porcine BM-MSCs
were similar to those of UC-MSCs (Figure 1A). The
supernatant of porcine UC-MSCs was plated in cell cul-
ture dishes. The cells were generally spindle-like and of
different sizes, and the nucleus could not be identified.
After 48 hours of cultivation in vitro, a few cells climbed
from the edges of adherent tissue. During cultivation,
the cells displayed colony growth, and most of the cellswere spindle-like, although there were several polygonal-
like cells as well. When the proliferating cell community
integrated, the cells were arranged directionally, showing
vortex-like growth (Figure 1A).
The purity of UC-MSCs and BM-MSCs was deter-
mined by flow cytometry. Cells with fluorescence in the
range of M1 were considered positive cells, which were
recognized by antibody detection. The auto-fluorescence
intensity was less than 101. The cells detected in this
range were negative. Overlay histogram of each cell
marker and its isotype antibody was made with Flowing
Software (version 2.5.1). UC-MSC verification was per-
formed by surface antigen expression, including the fol-
lowing four markers: positive for CD90, negative for
vascular endothelial cell marker antigen CD31, negative
for hematopoietic stem cell marker antigen CD34, and
negative for leukocyte marker antigen CD45 (Figure 1B)
(Additional file 1: Figure S3). The BM-MSC verification
included the following five markers: positive for CD29,
CD44, and CD90 and negative for CD34 and CD45
(Figure 1C) (Additional file 1: Figure S4).
Porcine mesenchymal stem cells can differentiate into
adipocytes and osteoblasts by in vitro induction
Osteogenic MSCs were stained with Alizarin Red.
Clumps or a sheet of orange-red precipitate appeared in
the intercellular space and were regarded as calcium
nodules on the cell surface (Figure 2A). Adipogenic
MSCs were stained by Oil Red. Orange fat particle drops
in cells were regarded as fat synthesized during differen-
tiation (Figure 2B). These results indicate that porcine
MSCs have the ability to differentiate in vitro. The
osteogenic and adipogenic differentiation potentials were
used as the evaluation criteria of MSCs in our work. We
did not conduct any quantitative assessment of osteo-
genic, adipogenic, and chondrogenic differentiation.
Analysis of differentially expressed proteins detected in
iTraqs and gene ontology enrichment analyses of these
proteins
The samples were detected by using two independent
iTRAQ-MS replicates. The DEPs were identified as pro-
teins that had an absolute value of the log of the ratio of
protein expression levels in UC-MSCs compared with
BM-MSCs greater than 0.144 (specifically, the protein
level between UC-MSCs and BM-MSCs differed by at
Figure 2 Mesenchymal stem cells could differentiate into adipocyte osteoblasts by induction in vitro. (A) Osteogenesis of bone marrow mesenchymal
stem cells (BM-MSCs) and umbilical cord mesenchymal stem cells (UC-MSCs). After osteogenic induction, many calcium deposits appeared in
osteocytes, which were stained red with Alizarin Red. (B) Adipogenesis of BM-MSCs and UC-MSCs. The lipid droplets generated in adipocytes were
stained red with Oil Red O. Scale bars, 100 μm.
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the first and second MS replicates, respectively, and 95
DEPs were detected in total (Figure 3A and Table 1).
There were five proteins whose expression levels be-
tween UC-MSCs and BM-MSCs were at least 10-folddifferent, namely, LGALS3, VIM, TMSB4X, CALD1, and
P4HA1 (Table 1). In total, 67 DEPs were detected in
both MS replicates, and the differential trend of these
proteins is consistent between the replicates (Figure 3A
and Table 1). In addition, the reproducibility of the
Figure 3 (See legend on next page.)
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Figure 3 Summary of differentially expressed proteins (DEPs) detected in two iTraq experiments and Gene Ontology enrichment analyses of DEPs.
(A) Overview of DEPs in two iTraq experiments. (B) An x-y scatter plot used to analyze the consistency of two sets of iTraq data, whereby the x-axis
represents the log value of the protein level in the UC-MSC-to-BM-MSC (UC/BM) ratio in the first mass spectrometry detection, and the y-axis
represents that parameter in the second detection. Histograms showing DEP enrichment in biological processes (C), cellular components
(D), and molecular functions (E). The enrichment degree was described by the ratio of the number of targeted proteins to all the annotated
proteins. BM-MSC, bone marrow mesenchymal stem cell; iTraq, isobaric tagging for relative and absolute quantitation; UC-MSC, umbilical cord
mesenchymal stem cell.
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cates was assessed by using a scatter plot (Figure 3B).
Briefly, the x-axis represents the log value of the iTRAQ
ratios of the UC-MSCs to BM-MSCs in the first MS rep-
licate, and the y-axis represents the iTRAQ ratios from
the second replicate. This scatter plot can be fit linearly
(Figure 3B) to obtain R2 and P values of 0.9737 and less
than 0.0001, respectively. Of the 95 DEPs, 89 were anno-
tated with GO terms by using the Sus scrofa GO annota-
tions database and European Bioinformatics Institute
Gene Ontology Annotation; we retrieved GO annotations
of all of these proteins, and the annotations are listed in
Additional file 1: Table S1. The GO enrichment analysis of
biological processes, cellular components, and molecular
functions showed that the enrichment degrees of DEPs in
biological regulation, metabolic processes, developmental
processes, immune system processes, reproduction, death,
growth, signaling, localization, response to stimulus, bio-
logical adhesion, and cellular component organization are
0.38, 0.408, 0.338, 0.07, 0.042, 0.042, 0.028, 0.113, 0.211,
0.225, 0.099, and 0.338, respectively (Figure 3C). The
degrees of DEP enrichment in the ribosome, nucleus,
mitochondrion, endosome, endoplasmic reticulum, Golgi
apparatus, vacuole, cytoskeleton, plasma membrane, cell
surface, extracellular matrix, and extracellular vesicular
exosome are 0.028, 0.254, 0.099, 0.028, 0.113, 0.028, 0.042,
0.282, 0.239, 0.07, 0.07, and 0.099, respectively (Figure 3D).
The degrees of DEP enrichment in structural molecule
activity, enzyme regulator activity, transporter activity,
antioxidant activity, catalytic activity, cyclic compound
binding, ion binding, small molecule binding, lipid
binding, carbohydrate binding, cofactor binding, and
protein binding are 0.113, 0.042, 0.028, 0.028, 0.296,
0.268, 0.408, 0.211, 0.056, 0.042, 0.028, and 0.746, re-
spectively (Figure 3E).KEGG pathway analysis of differentially expressed protein
indicated a remarkable difference in the motility capacity
between UC-MSCs and BM-MSCs
In total, 20 of 95 DEPs were mapped by using the
KEGG pathway database, and 37 pathways were ob-
tained (Additional file 1: Table S2). The primary path-
ways of the DEPs include energy metabolism, aminoacid metabolism, translation, folding-sorting degrad-
ation, signal transduction, cell motility, cell communi-
cation, and immune system (Figure 4A). Weighing the
fold changes of proteins in each pathway determined
that the weight in the cell motility pathway is the high-
est (Figure 4A). Moreover, 11 of 20 proteins could par-
ticipate in this pathway (Figure 4B) via mapping and
linking-related pathways. The results strongly suggest
that cell motility, including migration, invasion, and ad-
hesion, may be markedly different between UC-MSCs
and BM-MSCs.
Conformation of the differential expression of five
proteins
Significantly DEPs are most likely to affect cellular bio-
logical behavior. To verify the quantitative proteomic re-
sults, we chose Vimentin and LGALS3 because they
exhibited large differences in expression between the
two types of MSCs, whereas CTSB, TAGLN, and CNN1
were randomly selected for Western blotting verification
(Figure 5). The Western blot results are in agreement
with the iTRAQ results. Therefore, the results of the
Western blotting analysis confirmed the reliability of the
proteomic analysis.
The cell migration ability of BM-MSCs is higher than that
of UC-MSCs
The proteomic data displayed many DEPs related to cell
migration, such as Vimentin, LGALS3, FSCN1, TAGLN,
and CTSB (Table 1). Scratch and transwell assays were
used to detect the migration ability of MSCs. The results
of the migration assay showed that BM-MSCs had a
greater migration ability than UC-MSCs (Figure 6A, B).
Vimentin protein positively modulates mesenchymal stem
cell migration
Additionally, we found that the expression of the
vimentin gene is higher in BM-MSCs than in UC-MSCs
(Table 1). The Vimentin protein has been positively re-
lated to the high metastasis of tumor cells and lympho-
cytes. Therefore, vimentin may play an important role
in MSC migration. To test this function, we knocked
down vimentin in BM-MSCs and overexpressed this
Table 1 Differentially expressed proteins detected by two iTraq experiments
UniProt accession
number




A3EX84 Galectin LGALS3 −1.50000007 −1.66800008
P02543 Vimentin VIM −1.59599994 −1.51599999
B3XXC3 N/A TMSB4X −1.41600004 −1.60800006
F1SNH3 N/A CALD1 −1.54000006 −1.38400002
A1X898 N/A P4HA1 −0.93999986 −1.05999998
F1SU97 N/A PSAP −0.94400011
F1SKI0 N/A MYH11 −0.85200015 −0.89600002
F1SK03 N/A ANPEP −0.96399985 −0.7479999
Q56VQ1 N/A Oas2 0.827999957
F1SEQ7 N/A FAM213A 0.772000048
F2Z5M2 N/A LOC100515138 −0.68800004 −0.7479999
F1RWW4 N/A PDLIM5 −0.78800002 −0.632
Q2YGT9 60S ribosomal protein L6 RPL6 0.70400004 0.695999967
D0G7F7 N/A TPM4 −0.76800012 −0.61199992
F1RQW2 N/A C4 −0.68800004
A9YUA9 N/A N/A −0.692 −0.58400011
A9GYW6 N/A APLE −0.63599995
B2LUG8 N/A N/A 0.680000019 0.568000024
F1RKW9 N/A MYO1D 0.676000031 0.559999932
F1SDX6 N/A TGM2 0.667999997 0.548000035
F1S663 N/A LAMC1 0.559999932 0.652000004
F1SKJ1 N/A MYH9 −0.56399995 −0.64799991
Q9TSX9 Peroxiredoxin-6 PRDX6 −0.752 −0.44400006
F1RGS2 N/A GBA 0.612000045 0.544000055
F1SLI3 Microtubule-associated protein MAP4 −0.64799991 −0.47600007
F1SMN1 N/A CALU −0.65599994 −0.46399992
F2Z557 N/A PABPC1 −0.51999998 −0.58800002
C6K7I0 Importin subunit alpha N/A 0.551999967 0.544000055
P20112 SPARC SPARC −0.59199998 −0.496
P27594 Interferon-induced GTP-binding protein Mx1 MX1 0.480000049 0.572000047
F1S4Y8 N/A LOC100621044 −0.52399996
F1RSC3 N/A SCPEP1 0.52399994
C0LZL0 Fascin FSCN1 −0.548 −0.496
F1RJL6 N/A CLIP2 −0.51199996
F1SAP4 N/A WARS −0.5080001
Q08092 Calponin-1 CNN1 0.508000041
F1RST0 N/A HSPH1 0.476000051 0.512000015
F2Z5K2 Proteasome subunit alpha type PSMA5 0.476000051 0.476000051
F1RRV6 N/A NDRG1 −0.45599997 −0.48000003
F1SJS8 N/A TAGLN −0.496 −0.43599995
F1SLA0 ATP synthase subunit beta ATP5B 0.431999947 0.47199996
F1SQ11 N/A EEA1 −0.48799998 −0.41200004
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Table 1 Differentially expressed proteins detected by two iTraq experiments (Continued)
F1S764 N/A CPT2 0.427999945
A5A768 N/A AP3D1 0.427999945
F1S554 N/A PALMD −0.40800001 −0.44400006
F1SGP8 N/A RCN1 −0.40800001 −0.43999996
F1SMN5 N/A FLNC 0.41199995 0.431999947
F1S827 N/A SERBP1 −0.41599992
F1SMV6 N/A LOC100737174 −0.30800003 −0.50399997
A8CYB8 N/A RIG-I 0.384000008 0.420000017
F1SIJ9 N/A PSAT1 −0.39999997
F1SV06 N/A PABPC4 −0.37600003 −0.38400001
F1RKG8 N/A PEBP1 −0.37600003 −0.38400001
F1S9A4 N/A NUCB2 −0.38799997 −0.36800001
F2Z5C1 Annexin ANXA5 0.360000074
B6CVD6 N/A TXNDC4 0.344000043
F1SC51 N/A N/A 0.344000043
F1RI39 N/A LOC100517284 0.319999994 0.364000018
F1SPP8 N/A CKAP4 −0.29599998 −0.36400003
F1SJJ5 N/A RPL4 0.331999906 0.327999994
F1RJ93 N/A TAGLN2 −0.33999999 −0.31599999
F1SS24 N/A FN1 −0.35199996 −0.30400001
F1RRU7 N/A MRC2 −0.34399997 −0.31199999
F1SGJ6 N/A SLMAP 0.29600007 0.344000043
P33198 Isocitrate dehydrogenase [NADP], mitochondrial IDH2 0.327999994 0.299999937
F1RWJ5 N/A KPNB1 0.292000077
F1S3M9 N/A EPB41L2 0.29600007 0.288000032
F1SSA6 N/A LOC396903 −0.30800003 −0.27600005
B0LY42 N/A N/A −0.27199999 −0.30400001
P28491 Calreticulin CALR −0.28400001
Q4GWZ2 40S ribosomal protein SA RPSA 0.315999943 0.224000024
B2CNZ7 N/A CTSB −0.26399998
F1SIX3 N/A UGP2 −0.24799998 −0.25600002
F1SJR7 N/A TTLL12 −0.23199998 −0.26399998
G9F6X8 N/A N/A 0.275999909 0.208000125
F1RWT2 N/A PLS3 0.199999944 0.284000063
B5L0Y2 N/A CAST −0.24000005
F1RGP1 N/A MYBBP1A 0.211999977 0.244000118
Q5MJE5 N/A N/A −0.22800001
Q06AT0 Hippocalcin-like protein 1 HPCAL1 −0.22800001
F1RI15 N/A HSPA4 0.220000031
F1SFZ8 N/A TLN1 −0.22800001 −0.21199999
Q8SPT0 N/A N/A 0.21600007
D0G0C6 Asparagine synthetase ASNS −0.224 −0.20799999
F1RS36 N/A HSPA5 −0.25200001 −0.17999995
F1SQK1 N/A N/A −0.21999997 −0.17999995
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Table 1 Differentially expressed proteins detected by two iTraq experiments (Continued)
F1S0V3 Annexin ANXA6 0.183999971 0.203999991
F1SK12 N/A MAP1B −0.15599999 −0.21600001
F1SL58 N/A LOC100519091 −0.18400006
Q59IP2 N/A COL5A2 −0.18400006
Q29092 Endoplasmin HSP90B1 0.167999844 0.179999932
F1S596 N/A PRKCSH −0.15999999 −0.15999999
P80021 ATP synthase subunit alpha, mitochondrial ATP5A1 0.144000063 0.156000041
F1RR78 N/A LOC100049693 0.151999844 0.144000063
B0LXK8 N/A HPRT1 −0.144
iTraq, isobaric tagging for relative and absolute quantitation; N/A, not applicable; UC/BM, umbilical cord mesenchymal stem cell/bone marrow mesenchymal
stem cell.
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(Additional file 1: Figure S1). As shown in Figure 6C
and D, the knockdown of vimentin in BM-MSCs limits
their migration ability; however, vimentin overexpres-
sion in UC-MSCs promotes migration. These results
suggested that the higher migration capability of BM-
MSCs may be due to the higher expression of migration-
related protein than UC-MSCs.
Discussion
In recent years, adult MSCs have been widely used in re-
generative medicine research, and these cells can be iso-
lated from various tissues. Two types of MSCs were
used in this study: UC-MSCs and BM-MSCs. These cells
have similar biological characteristics and immunophe-
notypes. Because UC-MSCs have the advantages of both
convenience and ease of cell isolation, they may be used
as an alternative therapy candidate over BM-MSCs,
which are more difficult to isolate [2]. In addition, com-
parative proteomic studies indicate that UC-MSCs have
a high degree of overlap in protein expression profiles
with MSCs compared with embryonic stem cells [4].
UC-MSCs also display differences in their osteogenic
differentiation phenotypes. For example, UC-MSCs show
few Alizarin Red-positive deposits compared with BM-
MSCs; however, the associated mechanism is unclear
[17]. Interestingly, comparative proteomic analyses of
porcine BM-MSCs and UC-MSCs have not been re-
ported. Therefore, analyzing the DEPs between these
two sets of porcine MSCs may reveal molecular mecha-
nisms underlying the self-renewal, differentiation, and
tissue homing capacity of these cells and may provide a
theoretical basis for the clinical application of MSCs in
cell therapy and regenerative medicine [1].
During cell therapy, the integration of the donor cells or
biological material and the damaged tissue is dependent
on cell migration, differentiation, and matrix remodeling
[2,17,18]. In this study, BM-MSCs and UC-MSCs wereisolated from newborn piglets, and their cell surface
marker molecules, such as CD29, CD31, CD34, CD44,
CD45, and CD90, were identified during osteogenic and
adipogenic differentiation assays to determine the in vitro
cell homozygosity of MSCs and to maintain pluripotency.
In this study, we used iTRAQ labeling coupled with
LC-MS/MS to conduct a quantitative analysis of DEPs
from porcine BM-MSCs and UC-MSCs. This method is
not only gel-free but also sensitive and can detect many
low-abundance proteins often missed by other proteomic
methods. The results showed that 95 DEPs have at least a
39% difference in expression levels in two technical repli-
cates. The DEPs include five proteins that are expressed
10 times more highly in BM-MSCs: LGALS3, VIM,
TMSB4X, CALD1, and P4HA1. Three of these proteins
were reviewed porcine proteins in the Swiss-Prot protein
database, LGALS3, VIM, and TMSB4X, and two were
automatically annotated, CALD1 and P4HA1. These pro-
teins may play important roles in the process of cell
biology.
We subjected 20 of the DEPs to KEGG pathway ana-
lysis and identified several pathways involved in many
aspects of cell biology, including metabolism, genetic in-
formation processing, environmental information pro-
cessing, cellular processes, and organismal systems. The
most highly represented pathway for the DEPs is the cell
motility pathway. Protein detection methods used in our
experiment could analyze only the expression level of
each protein between different MSCs. But variations in
the level of phosphorylation of proteins would not be de-
tected. And in different types of cells, effects of protein
phosphorylation on pathway could hardly be compared.
However, we attempted to detect the phosphorylation of
AKt and Erk in MSCs which showed that phosphorylation
of both proteins increased significantly in the BM-MSCs
(Additional file 1: Figure S2).
Moreover, we observed that some structural proteins,
which are important for structural support of the cell
Figure 4 KEGG pathway analysis of DEPs indicated a remarkable difference in motility capacity between UC-MSCs and BM-MSCs. (A) A bubble
graph describing the distribution of DEPs in a classified KEGG pathway. The bubble size represents the differential protein expression level. The
dark bubbles show that the protein level in UC-MSCs is higher than that in BM-MSCs, whereas the light bubbles show the opposite trend. (B) A
KEGG pathway map with additional manual annotations and links. The red boxes represent the DEPs detected in the experiment. The red boxes
with red oval frames existed in the original KEGG pathway, and the red boxes with no oval frames and red links were added in line with a related
KEGG pathway. BM-MSC, bone marrow mesenchymal stem cell; DEP, differentially expressed protein; KEGG, Kyoto Encyclopedia of Genes and
Genomes; UC-MSC, umbilical cord mesenchymal stem cell.
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Figure 5 Confirmation of different expression of five proteins. The
relative expression levels of five proteins—Vimentin, LGALS3, CTSB,
TAGLN, and CNN1—in bone marrow mesenchymal stem cells
(BM-MSCs) and umbilical cord mesenchymal stem cells (UC-MSCs)
were confirmed with proteomic results.
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expressed in these MSCs. Compared with UC-MSCs,
VIM is upregulated, whereas CNN1, MYO1D, and PLS3
are downregulated in BM-MSCs. It has been shown that
the expression of CNN1 in smooth muscle increased
after transforming growth factor-beta (TGFβ) induced
BM-MSC differentiation [19]. In this study, the expres-
sion of CNN1 was downregulated in a time-dependent
manner (data not published) during the osteogenic dif-
ferentiation of BM-MSCs. Interestingly, the proteomic
results showed that the CNN1 expression level in BM-
MSCs was half that of UC-MSCs. Moreover, the osteo-
genic differentiation experiment suggested that the
differentiation ability of BM-MSCs is greater than that
of UC-MSCs. Taken together, these results suggest that
CNN1 may play an inhibitory role in the osteogenic differ-
entiation of MSCs. These results suggest that the BM-
MSCs and UC-MSCs may have some differences in cell
motility, including migration, invasion, and adhesion.
In these experiments, the pathway analysis was per-
formed by weighting the analysis with protein abun-
dance data to achieve a better understanding of the
differences present in these MSCs. This methodology,compared with analysis methods that consider only the
amount of proteins, more comprehensively highlight the
different pathways activated in these cells.
Related reports regarding the proteomic differences
between human BM-MSCs and UC-MSCs have been
published. These studies showed that the expression of
proteins that are positive regulators of cell migration,
such as LGALS3, VIM, and TMSB4X, are significantly
higher in BM-MSCs compared with UC-MSCs and that
the expression levels of negative regulators are signifi-
cantly reduced. Meanwhile, cell migration assays re-
vealed a higher migration ability of BM-MSCs. The
relationship between VIM and MSC migration is not
well understood. Therefore, we compared the role of
VIM in the migration phenotype of porcine BM-MSCs
and UC-MSCs. Vimentin was identified in these experi-
ments to be positively related in MSC migration. This
type III intermediate filament protein is abundantly
expressed in MSCs and in endothelial cells [20]. Al-
though Vimentin is a basic regulatory protein involved
in many physiological processes, such as intracellular
homeostasis, cell viability, endothelial integrity, and ner-
vous system injury, vimentin gene knockout mice
showed no obvious barriers to embryonic development
and had no effect on the survival of individuals [20,21].
To explore the role of the Vimentin protein in MSC mi-
gration, the expression of this protein was knocked
down in BM-MSCs and overexpressed in UC-MSCs in
our study. Scratch injury and transwell migration tests
showed that the migration ability of BM-MSCs was sig-
nificantly higher than that of UC-MSCs, and this ability
is associated with the up-regulated expression of the
Vimentin protein. In addition, Rogel MR et al. reported
that, in alveolar epithelial cells, TGFβ1 could enhance
the expression of Vimentin [22]. However, in our prote-
omic data, we did not find any difference in expression
of TGFβ1 between BM-MSCs and UC-MSCs. When the
vimentin gene was deleted, the expression of adhesion
molecules was impaired, thereby reducing the adhesion
and trans-endothelial migration rate of lymphocyte
cells [23]. A close relation between Vimentin and cancer
cell migration capabilities has also been found [24-26].
LGALS3, which is the third member of the galactosidase
lectin protein family, was significantly increased in BM-
MSCs, and this protein plays an important role in cell pro-
liferation, adhesion, migration, and apoptosis [27-32].
The expression of TMSB4X, a major G-actin-seques-
tering peptide that is largely distributed in various cells
and in the circulatory system and that is capable of
binding to G-actin to inhibit actin aggregation, was sig-
nificantly more highly expressed in BM-MSCs than in
UC-MSCs [33,34]. TMSB4X promoted increased expres-
sion of MMP-1, MMP-2, and MMP-3 as well as the se-
cretion of plasminogen activator inhibitor-1 (PAI-1),
Figure 6 (See legend on next page.)
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Figure 6 The cell migration ability of bone marrow mesenchymal stem cells (BM-MSCs) was higher than that of umbilical cord mesenchymal stem
cells (UC-MSCs), which might be related to Vimentin. (A) Zero, six, 12, 24, 36, and 48 hours after scratching in BM-MSCs and UC-MSCs, respectively.
Downward lines were drawn to show the healing rate of each scratching even. (B) Transwell results of wild-type BM-MSCs and UC-MSCs. (C, D) The
effect of Vimentin expression on the migration of BM-MSCs and UC-MSCs. The expression of Vimentin was reduced in BM-MSCs (C) and elevated in
UC-MSCs (D). As the histograms showed, the migration effect of BM-MSCs is higher than that of UC-MSCs and positively correlated with the expression
of Vimentin. ***P <0.01. Bars show the standard error of the mean. Magnifications: 4× (A) and 40× (B-D).
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tion [35]. The regulation of cell migration by TMSB4X
is cell-specific. In endothelial cells, the transcription
level of PAI-1 is enhanced by TMSB4X [35]. However,
comparative proteomic studies of BM-MSCs and UC-
MSCs showed that the expression of PAI-1 in BM-MSCs
was significantly lower than that in UC-MSCs, and the
cell migration assay results indicated that PAI-1 is a
negative regulator of cell migration in MSCs [2]. Thus,
the effect of TMSB4X on endothelial cell migration is
most likely regulated by a complex variety of factors. In
tumor cells, TMSB4X can promote cell migration and
vascular endothelial growth factor-induced angiogenesis,
thereby accelerating tumor growth and metastasis
[36,37]. Lastly, TMSB4X is an anti-inflammatory factor
that could accelerate the repair of skin and corneal
burns, a process which is closely related to cell migration
promoted by TMSB4X [38].
One interesting result of this study is that proteins re-
lated to the immune response, such as PRKCSH, Oas2,
and RIG-I, are differentially expressed between BM-
MSCs and UC-MSCs. PRKCSH is a regulatory subunit
of glucosidase II and is expressed predominantly in the
endoplasmic reticulum [39]. In fetal tissue, PRKCSH is
expressed in the ductal plate, bile ducts, and hepato-
cytes, suggesting that PRKCSH is most likely required
for bile duct development [39]. RIG-I is a member of the
RIG-I-like receptor family and plays a major role in
pathogen sensing of RNA virus infection to induce type
I interferon production [40]. However, strong evidence
has shown that significant induction of RIG-I occurs
during normal myelopoiesis and that the development of
a progressive myeloproliferative disorder is disrupted
when Rig-I is knocked down [41].Conclusions
This study is the first of its kind to perform a quantitative
analysis of DEPs between porcine BM-MSCs and UC-
MSCs, combined with GO analysis, KEGG signaling
pathway analysis, and cell migration studies. These ex-
periments describe differences in the migration abilities
of these two types of cells. The data indicate that this dif-
ference in migration is related to the expression levels ofproteins, and therefore, they provide experimental evi-
dence for cell-based targeted therapy using MSCs.
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